• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【药物名称】

【化学名称】2-[3-(4-Chlorophenyl)-2-propenyl]-5,6-bis(4-methoxyphenyl)pyridazin-3(2H)-one

【CA登记号】225666-41-1

【 分 子 式 】C27H23ClN2O3

【 分 子 量 】458.94896

【开发单位】Kowa (Originator)

【药理作用】Antiarthritic Drugs, TREATMENT OF MUSCULOSKELETAL & CONNECTIVE TISSUE DISEASES, IL-1beta Production Inhibitors

合成路线1

Glyoxylic acid (II), generated in situ by oxidative cleavage of tartaric acid (I) with sodium periodate, was condensed with deoxyanisoin (III) to provide the aldol adduct (IV). Cyclization of hydroxyacid (IV) with hydrazine gave rise to the hydroxy dihydropyridazinone (V), which was further dehydrated to (VI) upon treatment with p-toluenesulfonic acid in refluxing benzene. Finally, alkylation of pyridazinone (VI) with 4-chlorocinnamyl chloride (VII) in the presence of potassium carbonate furnished the title compound.

1 Matsuda, T.; et al.; Synthesis and bioactivities of novel 5,6-bis(4-methoxyphenyl)-2H-pyridazin-3-one derivatives: Inhibitors of interleukin-1 beta (IL-1beta) production. Bioorg Med Chem Lett 2001, 11, 17, 2373.
2 Yoshizaki, H.; Habata, Y.; Kumai, N.; Kotaki, K.; Ohkuchi, M.; Ohgiya, T.; Yamazaki, Y.; Matsuda, T.; Kitamura, T.; Koshi, T.; Kyotani, Y.; Shigyo, H. (Kowa Co., Ltd.); Novel pyridazine derivs. and drugs containing the same as the active ingredient. EP 1043317; JP 1999152274; JP 2000198776; US 6348468; WO 9925697 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 52118 Uvic Acid; Tartaric acid; Dihydroxysuccinic acid; 2,3-Dihydroxybutanedioic acid 133-37-9 C4H6O6 详情 详情
(II) 15618 2-Oxoacetic acid; Glyoxylic Acid 298-12-4 C2H2O3 详情 详情
(III) 22991 1,2-bis(4-methoxyphenyl)-1-ethanone 120-44-5 C16H16O3 详情 详情
(IV) 52114 2-hydroxy-3,4-bis(4-methoxyphenyl)-4-oxobutyric acid C18H18O6 详情 详情
(V) 52115 4-hydroxy-5,6-bis(4-methoxyphenyl)-4,5-dihydro-3(2H)-pyridazinone C18H18N2O4 详情 详情
(VI) 52116 5,6-bis(4-methoxyphenyl)-3(2H)-pyridazinone C18H16N2O3 详情 详情
(VII) 52117 1-chloro-4-[(E)-3-chloro-1-propenyl]benzene C9H8Cl2 详情 详情
Extended Information